Skip to content

Titan Medical Pronounces Publication of Patent Utility Increasing Dedication to Continued Innovation in Single Entry Robotic Assisted Surgical procedure

Titan Medical Inc.

Strengthens firm’s mental property portfolio with improvements in subsequent technology single entry RAS know-how

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical system firm centered on the event and commercialization of progressive surgical applied sciences for single entry robotic-assisted surgical procedure (RAS), at this time introduced the publication of worldwide patent utility No. PCT/CA2022/050392, which the corporate anticipates pursuing in the USA and different key markets beneath the Patent Cooperation Treaty (PCT).

The patent utility typically discloses dexterous endoscope applied sciences to be used with RAS techniques which can be designed to offer a strong workspace discipline of view larger than these supplied by prior endoscope applied sciences, that are designed to seize solely a portion of a surgical web site. Know-how described within the patent utility could possibly be utilized in quite a lot of single entry RAS techniques, together with these designed to assist three devices which can be concurrently positionable inside an insertion conduit.

“It was vital for us to share the publication of this patent utility because it highlights our continued dedication to be an innovation chief in single entry RAS, which incorporates but in addition extends past the present growth of the Enos™ surgical system,” mentioned Cary Vance , President and CEO of Titan. “Whereas we’re centered on the event, scientific and regulatory actions for the Enos system, we’re dedicated to persevering with to advance the surgical expertise for sufferers, surgeons and hospitals by the analysis and growth of RAS know-how elements and techniques. Submitting patent purposes on our innovations stays an vital step in defending the worth we proceed to generate, together with these designed for next-generation applied sciences and techniques. As we additional innovate and develop our RAS know-how roadmap, we anticipate to increase our management in single entry innovation and mental property, competitively positioning Titan, significantly with respect to imminent RAS entrants.”

Titan has developed an expansive mental property portfolio with over 220 pending and issued patents masking the USA and different jurisdictions that assist and canopy varied features of single-access RAS together with the Enos system’s surgeon workstation, affected person cart, dexterous articulating devices, ergonomic hand- controllers, enhanced imaginative and prescient techniques, superior management software program, and instinctive surgeon overlays for offering interoperative suggestions. This protection of single-access RAS, and specifically the Enos system, together with protection of extra common features of RAS applied sciences, might present the corporate with a number of mental property choices together with additional defending its RAS applied sciences, and the potential to additional license its applied sciences. and help in securing a aggressive business pathway.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical system firm headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina, is targeted on enhancing robotic assisted surgical procedure (RAS) utilizing progressive know-how by a single entry level . The Enos™ robotic single entry surgical system is being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand and contains multi-articulating devices designed to permit surgeons an elevated vary of movement in a confined area, with dexterity and the flexibility to exert the forces essential to finish widespread surgical duties. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

Enos™ is a trademark of Titan Medical Inc.

For extra info, go to www.titanmedicalinc.com and observe @TitanMedical on Twitter and LinkedIn.

Ahead-Wanting Statements

This information launch incorporates “forward-looking statements” inside the that means of relevant Canadian and US securities legal guidelines, which replicate the present expectations of administration of the corporate’s future development, outcomes of operations, efficiency and enterprise prospects and alternatives. Ahead-looking statements are continuously, however not all the time, recognized by phrases akin to “might”, “would”, “may”, “will”, “anticipate”, “consider”, “plan”, “anticipate”, “intend ”, “estimate”, “potential for” and comparable expressions, though these phrases might not be current in all forward-looking statements. Ahead-looking statements that seem on this launch might embody, with out limitation, references to: the corporate’s plans beneath the PCT; the potential benefits of the corporate’s applied sciences together with dexterous endoscope applied sciences offering a strong workspace discipline of view; the know-how described within the patent utility being utilized in quite a lot of single entry RAS system; the corporate’s dedication to being an innovation chief in single entry RAS, which incorporates but in addition extends past the Enos system; the corporate’s dedication to advance the surgical expertise for sufferers, surgeons and hospitals; the corporate’s expectation to increase its management in single entry improvements and mental property; the corporate’s aggressive place, together with with respect to imminent RAS entrants; the protection of and the choices supplied by the corporate’s mental property portfolio; the Enos robotic single entry surgical system being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand; and that Titan intends to initially pursue gynecologic surgical indications. These statements replicate administration’s present beliefs with respect to future occasions and are primarily based on info at the moment out there to administration. Ahead-looking statements contain important dangers, uncertainties and assumptions. Many elements may trigger the corporate’s precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements that could be expressed or implied by such forward-looking statements, together with, with out limitation, these listed within the “Danger Elements” part of the corporate’s Annual Report for the fiscal 12 months ended December 31, 2021 which can be considered at www.sedar.com and at www.sec.gov. Ought to a number of of those dangers or uncertainties materialize, or ought to assumptions underlying the forward-looking statements show incorrect, precise outcomes, efficiency, or achievements might fluctuate materially from these expressed or implied by the forward-looking statements contained on this information launch. These elements ought to be thought-about rigorously, and potential buyers shouldn’t place undue reliance on the forward-looking statements. Though the forward-looking statements contained within the information launch are primarily based upon what administration at the moment believes to be affordable assumptions, the corporate can not guarantee potential buyers that precise outcomes, efficiency or achievements shall be in step with these forward-looking statements. Besides as required by legislation, the corporate expressly disclaims any intention or obligation to replace or revise any forward-looking statements whether or not on account of new info, future occasions or in any other case.

Contact
Kristen Galfetti
Vice President, Investor Relations
& Company Communications
+1-781-869-2553
buyers@titanmedicalinc.com

###

Leave a Reply

Your email address will not be published.